HAVCR2 and acute myeloid leukemia: Haubner et al. indicate that combinatorial targeting of CD33/TIM3 or CLL1/TIM3 may enhance therapeutic efficacy without aggravating toxicity in immunotherapy of AML Leukemia [82].